483 Apertus Pharmaceuticals Jan 2020

483 Apertus Pharmaceuticals Jan 2020

Robert Ham FDA, Michele Perry-Williams FDA, Ana Sandee FDA$119.00 - Available Now

FDA investigators audited the Apertus Pharmaceuticals - Ballwin, MO, United States facility and issued inspectional observations (via FDA 483) on 16 Jan 2020.

Product details

  • Category: Human Drugs
  • Inspection end: 16 Jan 2020
  • Location: Ballwin, United States
  • FEI: 3010401502
Add To Cart